store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CCT018159 是一种 3,4-二芳基吡唑间苯二酚,是一种 ATP 竞争性HSP90ATPase 抑制剂,对人 Hsp90β 和酵母 Hsp90 具有抑制作用,IC50分别为 3.2 和 6.6 μM。CCT018159 抑制与侵袭和血管生成有关的关键内皮细胞和肿瘤细胞功能。CCT018159 引起与 G1 期阻滞相关的细胞抑制并诱导细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 315 | 现货 | ||
5 mg | ¥ 742 | 现货 | ||
10 mg | ¥ 1,150 | 现货 | ||
25 mg | ¥ 2,310 | 现货 | ||
50 mg | ¥ 3,460 | 现货 | ||
100 mg | ¥ 4,930 | 现货 |
产品描述 | CCT018159 is a 3,4-diarylpyrazole resorcinol, an ATP-competitive HSP90ATPase inhibitor that inhibits human Hsp90β and yeast Hsp90 with IC50s of 3.2 and 6.6 μM, respectively.CCT018159 inhibits key endothelial and tumor cell functions associated with invasion and angiogenesis. CCT018159 caused cellular inhibition associated with G1 phase block and induced apoptosis. |
靶点活性 | HSP90 β (human):3.2 μM, HSP90 (yeast):6.6 μM, HSP90:3.2 µM |
体外活性 | CCT018159 (100 nM-10 μM) decreased POMC mRNA levels in AtT-20 cells and ACTH levels in the culture medium of these cells, suggesting that CCT018159 suppresses ACTH synthesis and secretion in corticotroph tumor cells. CCT018159 also decreased cell proliferation and induced apoptosis. FACS analyses revealed that CCT018159 agents increased the percentage of AtT-20 cells in the G2/M phase. CCT018159 decreased cell proliferation, presumably due to the induction of cell death and arrest of the cell cycle in AtT-20 cells.[1] |
体内活性 | CCT018159 (4 mg/mouse; s.c.; ones daily for 14 days; AtT-20-xenografted mice) reduced tumor weight compared to AtT-20-xenografted control mice. CCT018159 also decreased plasma ACTH levels, and POMC and PTTG1 mRNA levels in the tumor cells.[2] |
分子量 | 352.38 |
分子式 | C20H20N2O4 |
CAS No. | 171009-07-7 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (319.3 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8378 mL | 14.1892 mL | 28.3785 mL | 70.9461 mL |
5 mM | 0.5676 mL | 2.8378 mL | 5.6757 mL | 14.1892 mL | |
10 mM | 0.2838 mL | 1.4189 mL | 2.8378 mL | 7.0946 mL | |
20 mM | 0.1419 mL | 0.7095 mL | 1.4189 mL | 3.5473 mL | |
50 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.4189 mL | |
100 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.7095 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CCT018159 171009-07-7 Apoptosis Cytoskeletal Signaling Metabolism HSP CCT 018159 CCT-018159 Inhibitor inhibitor inhibit